Metallothionein II treatment mitigates rotenone-induced neurodegeneration in zebrafish models of Parkinson’s disease
IntroductionParkinson’s disease (PD) is a common neurodegenerative disorder primarily affecting motor function due to progressive loss of dopaminergic neurons in the substantia nigra. Current therapies offer symptomatic relief but fail to halt disease progression, highlighting the need for novel the...
Saved in:
Main Authors: | Yong Hui Nies, Wei Ling Lim, Norwahidah Abd Karim, Mohamad Fairuz Yahaya, Seong Lin Teoh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1478013/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The interaction of tPA with NMDAR1 drives neuroinflammation and neurodegeneration in α-synuclein-mediated neurotoxicity
by: Daniel Torrente, et al.
Published: (2025-01-01) -
Stat3 mediates Fyn kinase-driven dopaminergic neurodegeneration and microglia activation
by: Sahiba Siddiqui, et al.
Published: (2024-12-01) -
Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives
by: Virendra Kumar Yadav, et al.
Published: (2025-01-01) -
Nanodiamond-mediated delivery of microRNA-7 for the neuroprotection of dopaminergic neurons
by: Yuping Han, et al.
Published: (2025-01-01) -
Induced pluripotent stem cell–related approaches to generate dopaminergic neurons for Parkinson’s disease
by: Ling-Xiao Yi, et al.
Published: (2025-11-01)